Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
Authors:
- Suayib YalcinSYSuayib Yalcin
- Faysal DaneFDFaysal Dane
- Berna OksuzogluBOBerna Oksuzoglu
- Nuriye Yildirim OzdemirNONuriye Yildirim Ozdemir
- Abdurrahman IsikdoganAIAbdurrahman Isikdogan
- Metin OzkanMOMetin Ozkan
- Guzin Gonullu DemiragGDGuzin Gonullu Demirag
- Hasan Senol CoskunHCHasan Senol Coskun
- Bulent KarabulutBKBulent Karabulut
- Turkkan EvrenselTETurkkan Evrensel
- Mehmet Ali UstaogluMUMehmet Ali Ustaoglu
- Feyyaz OzdemirFOFeyyaz Ozdemir
Open Access
- 30 March 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-7
Abstract
Background: Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown. Methods: A total of 125 patients were randomized to combination therapy (1000 mg/m2 gemcitabine + 125 mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000 mg/m2) arms to take treatment weekly for 7 of 8 weeks, and following 3 of 4 weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL. Results: Overall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p = 0.018). These proportions were 27.3 and 36.6% in 6th month assessments, respectively (p = 0.357). Median overall survivals in combination and single-agent arms were 9.92 months and 5.95 months, respectively (HR: 0.64, 95% CI: 0.42–0.86, p = 0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22 months, respectively (HR: 0.58, 95% CI: 0.39–0.87, p = 0.008). Median time-to-deterioration were 5.36 vs 3.68 months, and objective response rates were 37.1% vs 23.7% (p = 0.009), respectively in combination and single-agent arms. Conclusions: Combination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer. Trial registration: This study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered).Keywords
Funding Information
- Türk Tıbbi Onkoloji Derneği (wwww)
- Türk Kanser Araştirma ve Savaş Kurumu Derneği (awe)
- hacettepe onkoloji derneği (wwww)
- Celgene (aaaa)
- onkoloji araştırmaları derneği (aaa)
This publication has 12 references indexed in Scilit:
- Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic reviewCritical Reviews in Oncology/Hematology, 2016
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized TrialJournal of Clinical Oncology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Symptom profiles and palliative care in advanced pancreatic cancer—a prospective studySupportive Care in Cancer, 2006
- Health-Related Quality of Life in Patients with Pancreatic CancerDigestion, 2006
- Recent Updates on the Role of Chemotherapy in Pancreatic CancerSeminars in Oncology, 2005
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaAnnals of Oncology, 2002
- A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBritish Journal of Cancer, 2002